Metsera, Inc. (NASDAQ:MTSR - Get Free Report) shares dropped 7.6% during trading on Monday . The company traded as low as $23.55 and last traded at $23.70. Approximately 169,960 shares traded hands during mid-day trading, a decline of 80% from the average daily volume of 866,117 shares. The stock had previously closed at $25.65.
Analyst Ratings Changes
Several equities research analysts have issued reports on the company. Cantor Fitzgerald initiated coverage on Metsera in a report on Tuesday, February 25th. They set an "overweight" rating on the stock. Guggenheim initiated coverage on shares of Metsera in a research note on Tuesday, February 25th. They set a "buy" rating and a $56.00 price objective on the stock. Bank of America initiated coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued a "buy" rating and a $38.00 target price for the company. Finally, Evercore ISI started coverage on shares of Metsera in a research report on Tuesday, February 25th. They set an "outperform" rating on the stock.
Read Our Latest Stock Report on MTSR
Metsera Trading Down 3.6 %
The company has a 50 day moving average of $22.80.
Metsera (NASDAQ:MTSR - Get Free Report) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($3.52) earnings per share (EPS) for the quarter.
Institutional Investors Weigh In On Metsera
A number of institutional investors and hedge funds have recently bought and sold shares of the business. New York State Common Retirement Fund bought a new stake in shares of Metsera in the 1st quarter worth approximately $131,000. Deutsche Bank AG bought a new stake in shares of Metsera during the 1st quarter worth $374,000. Bank of New York Mellon Corp acquired a new position in shares of Metsera in the 1st quarter worth $884,000. TD Asset Management Inc acquired a new stake in shares of Metsera during the first quarter worth $2,091,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in shares of Metsera during the first quarter valued at $3,410,000.
Metsera Company Profile
(
Get Free Report)
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
See Also
Before you consider Metsera, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Metsera wasn't on the list.
While Metsera currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
